Beta Cryptoxanthin, Beta-Cryptoxanthin
| Name | Beta-Cryptoxanthin | ||
| PubChem CID | 5281235 | ||
| Molecular Weight | 552.9g/mol | ||
| Synonyms |
Beta Cryptoxanthin, Beta-Cryptoxanthin |
||
| Formula | C₄₀H₅₆O | ||
| SMILES | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CC(CC2(C)C)O)C)C)C | ||
| InChI | 1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1 | ||
| InChIKey | DMASLKHVQRHNES-FKKUPVFPSA-N | ||
| CAS Number | 472-70-8 | ||
| ChEBI ID | CHEBI:10362 | ||
| Drug Bank ID | DB15914 | ||
| KEGG ID | C08591 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | ChenPi | ||
| Use Part | Pericarp | ||
| Habitat | FuJian, TaiWan, GuangDong, GuangXi | ||
| Flavor | Bitter, Pungent | ||
| Meridian Tropism | Lung, Spleen | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Sapindales
-->Family: Rutaceae
-->Genus: Citrus
-->Species: Citrus reticulata
|
||
| Chineses Pinyin | LaJiao | ||
| Use Part | Fruit | ||
| Habitat | China | ||
| Flavor | Pungent | ||
| Meridian Tropism | Heart; Spleen | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Solanales
-->Family: Solanaceae
-->Genus: Capsicum
-->Species: Capsicum annuum
|
||
| Pair Name | Beta-Cryptoxanthin, Oxaliplatin | |||
| Partner Name | Oxaliplatin | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | TP73 | hsa7161 |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| SW1417 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_1717 | |
| In Vivo Model | 1×10⁶ HCT116 cells and 1×10⁶ and 107 SW480 cells suspended in 20% matrigel were subcutaneously injected to nude mice (Hsd:Athymic Nude-Foxn1nu, female, 6 weeks old). | |||
| Result | We propose a putative novel therapeutic strategy for the treatment of colon cancer based on the combination of β-cryptoxanthin and oxaliplatin. The combined regimen produced more benefit than either individual modality without increasing side effects. In addition, the concentration-limiting toxicity of oxaliplatin is reduced in the presence of the carotenoid. | |||
